Note 2 - BASIS OF PRESENTATION AND MANAGEMENT'S PLANS	3 Months Ended
Jun. 30, 2015
Disclosure Text Block [Abstract]
Note 2 -- Basis of Presentation and Management's Plans	(a) Basis of presentation: The accompanying financial statements of Nemaura have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at June 30, 2015 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company's Annual Report on Form 10-K for the Year Ended March 31, 2015. The results of operations for the period ended June 30, 2015 are not necessarily an indication of operating results for the full year. The Company's operations are conducted in the United Kingdom. Accordingly, the political, economic, and legal environments in the United Kingdom may influence the Company's business, financial condition, and results of operations. The functional currency for the majority of the Company's operations is the Great Britain Pound Sterling ("GBP"), and the reporting currency is the US Dollar. (b) Management's plans: As reflected in the accompanying consolidated financial statements, the Company reported a net loss of approximately $403,000 and net cash used in operations of approximately $177,000 for the quarter ended June 30, 2015, an accumulated deficit of approximately $4,465,000, and a total deficit of approximately $1,332,000 at June 30, 2015. Nemaura Pharma Limited, a related company, has agreed to provide a loan facility should this be required to fund the company's operations through September 30, 2016. The Company believes that this loan facility in addition to the current working capital position, will be sufficient to meet its estimated cash needs for the remainder of 2015 and through September 30, 2016.

Note 2 - BASIS OF PRESENTATION AND MANAGEMENT'S PLANS

3 Months Ended

Jun. 30, 2015

Note 2 -- Basis of Presentation and Management's Plans

(a) Basis of presentation:

The accompanying financial statements of Nemaura have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at June 30, 2015 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company's Annual Report on Form 10-K for the Year Ended March 31, 2015. The results of operations for the period ended June 30, 2015 are not necessarily an indication of operating results for the full year.

The Company's operations are conducted in the United Kingdom. Accordingly, the political, economic, and legal environments in the United Kingdom may influence the Company's business, financial condition, and results of operations.

The functional currency for the majority of the Company's operations is the Great Britain Pound Sterling ("GBP"), and the reporting currency is the US Dollar.

(b) Management's plans:

As reflected in the accompanying consolidated financial statements, the Company reported a net loss of approximately $403,000 and net cash used in operations of approximately $177,000 for the quarter ended June 30, 2015, an accumulated deficit of approximately $4,465,000, and a total deficit of approximately $1,332,000 at June 30, 2015.

Nemaura Pharma Limited, a related company, has agreed to provide a loan facility should this be required to fund the company's operations through September 30, 2016. The Company believes that this loan facility in addition to the current working capital position, will be sufficient to meet its estimated cash needs for the remainder of 2015 and through September 30, 2016.